Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial-Reference-Cited by-同舟云学术

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Published:2017-12 Issue:12 Volume:5 Page:941-950
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Sabatine Marc S,Leiter Lawrence A,Wiviott Stephen D,Giugliano Robert P,Deedwania Prakash,De Ferrari Gaetano M,Murphy Sabina A,Kuder Julia F,Gouni-Berthold Ioanna,Lewis Basil S,Handelsman Yehuda,Pineda Armando Lira,Honarpour Narimon,Keech Anthony C,Sever Peter S,Pedersen Terje R

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. IDF Diabetes Atlas,2015

2. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study;Kannel;Am Heart J,1985

3. Diabetes and mortality following acute coronary syndromes;Donahoe;JAMA,2007

4. Type 2 diabetes;Chatterjee;Lancet,2017

5. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;Circulation,2014

Cited by 455 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study;Cardiology and Therapy;2024-01-29

2. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

3. Ischaemic Heart Disease in Diabetes;Textbook of Diabetes;2024-01-12

4. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke;Frontiers in Pharmacology;2024-01-11

5. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08